(NASDAQ: OVID) Ovid Therapeutics's forecast annual revenue growth rate of 274.95% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Ovid Therapeutics's revenue in 2024 is $391,695.On average, 2 Wall Street analysts forecast OVID's revenue for 2024 to be $43,133,013, with the lowest OVID revenue forecast at $28,283,943, and the highest OVID revenue forecast at $57,982,083. On average, 2 Wall Street analysts forecast OVID's revenue for 2025 to be $820,234,341, with the lowest OVID revenue forecast at $61,517,576, and the highest OVID revenue forecast at $1,578,951,107.
In 2026, OVID is forecast to generate $1,405,004,859 in revenue, with the lowest revenue forecast at $1,405,004,859 and the highest revenue forecast at $1,405,004,859.